- A library over 300 compounds with activity against a range of viruses, witch form the starting point for designing potent inhibitor specific point for design for viruses interest.
- pipeline, program indications with high unmet clinical need or large patients populations such as hepatitis c, HIV v clinical and dangue, zika influenza.
- robust clinical validation, completed 7 human clincial trials with strong, safety and efficacy outcomes.
- portfolio of patients and pentent applications directed to visitor's unique anti viral approach and each product candidt.
- pipe line :
Hep C compound BIT225 - 2 x phase II studies completed.
HIV-1 / HCV compound BIT225 - 1 x phase II study completed.
HIV- 1 BIT225 1 x phase study completed.
Next gen Hep c - discovery successfull, preclinical successfully. Phase 1 phase phase 2 still on going.
Dengue, influenza, zika - discovery suscusfull, preclincal / phase 1 / phase 2 still on going.
BIT Price at posting:
21.0¢ Sentiment: Buy Disclosure: Held
